Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors
Latest Information Update: 29 Feb 2024
At a glance
- Drugs Nintedanib (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours
- Focus Therapeutic Use
- 20 Jan 2024 Results assessing serum VEGF and LAG-3 expression to determine potential biomarkers of response in patients treated with nintedanib using 27 sets of paired samples fromthisb trial presented at the 2024 Gastrointestinal Cancers Symposium
- 09 Feb 2023 Status changed from active, no longer recruiting to completed.
- 08 Nov 2022 Planned End Date changed from 30 Sep 2022 to 30 Dec 2022.